RegeneRx Working With U.S. Military To Test Tβ4 Against Exposure To Chemical Agents In The Eye

Main Category: Eye Health / Blindness
Article Date: 24 Jun 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the "Company" or "RegeneRx") announced today that it is collaborating with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University, to evaluate Tβ4's (RGN-259 eye drops) ability to prevent or reduce damage to the eye caused by exposure to chemical agents. The ability to prevent or reduce such damage is the focus of substantial efforts by both the military and homeland security. The project will consist of a series of research experiments over the next twelve months with Tβ4, which is being commercially developed by RegeneRx and is in Phase II clinical trials.

Dr. Sosne and his colleagues have published several scientific articles describing Tβ4's ability to reduce damage from a number of different chemical agents by reducing inflammation and promoting re-epithelialization to repair the cornea. Other scientific teams have reported Tβ4's ability to promote stem cell differentiation to protect and repair tissue in the heart and skin.

"We are pleased to be working with U.S. military on this important project. We hope their work will lead to the use of our technology for treatment of eyes exposed to caustic chemicals. RegeneRx is prepared to assist in any way possible to support efforts to protect our military personnel and citizens from exposure to debilitating or life-threatening chemical agents," stated J.J. Finkelstein, RegeneRx's president and CEO.

Source
RegeneRx Biopharmaceuticals, Inc.

• Additional
• References
• Citations